Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA Jr, Kim YH.

Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25.

PMID:
31253572
2.

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N.

Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091.

3.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.

Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A.

Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3.

4.

Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.

Lhospice F, Brégeon D, Belmant C, Dennler P, Chiotellis A, Fischer E, Gauthier L, Boëdec A, Rispaud H, Savard-Chambard S, Represa A, Schneider N, Paturel C, Sapet M, Delcambre C, Ingoure S, Viaud N, Bonnafous C, Schibli R, Romagné F.

Mol Pharm. 2015 Jun 1;12(6):1863-71. doi: 10.1021/mp500666j. Epub 2015 Feb 9.

PMID:
25625323
5.

IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.

Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C, Bensussan A, Bagot M, Sicard H.

Cancer Res. 2014 Nov 1;74(21):6060-70. doi: 10.1158/0008-5472.CAN-14-1456.

6.

The toll-like receptor agonist imiquimod is active against prions.

Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C.

PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013.

7.

Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic.

Vérillaud B, Gressette M, Morel Y, Paturel C, Herman P, Lo KW, Tsao SW, Wassef M, Jimenez-Pailhes AS, Busson P.

Infect Agent Cancer. 2012 Dec 3;7(1):36. doi: 10.1186/1750-9378-7-36.

8.

TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA.

Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I, Demaria O, Viaud N, Gauthier L, Blery M, Bonnefoy-Berard N, Morel Y, Tschopp J, Alexopoulou L, Trinchieri G, Paturel C, Caux C.

J Immunol. 2010 Aug 15;185(4):2080-8. doi: 10.4049/jimmunol.1000532. Epub 2010 Jul 16.

9.

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells.

Friboulet L, Gourzones C, Tsao SW, Morel Y, Paturel C, Témam S, Uzan C, Busson P.

BMC Cancer. 2010 Jun 24;10:327. doi: 10.1186/1471-2407-10-327.

10.

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L.

Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12.

11.

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS.

Blood. 2010 Mar 11;115(10):1949-57. doi: 10.1182/blood-2009-08-238543. Epub 2010 Jan 11.

12.

Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides.

Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C.

Eur J Immunol. 2006 Dec;36(12):3256-67.

13.

First stereospecific synthesis of (E)- or (Z)-alpha-fluoroenones via a kinetically controlled Negishi coupling reaction.

Dutheuil G, Paturel C, Lei X, Couve-Bonnaire S, Pannecoucke X.

J Org Chem. 2006 May 26;71(11):4316-9.

PMID:
16709079
14.

The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor.

Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ.

J Exp Med. 2002 Apr 1;195(7):953-8.

15.

[Tuberculous rheumatism. Apropos of a case].

Saraux A, Le Corre E, Paturel C, Baron P, Le Goff P.

Rev Rhum Ed Fr. 1993 Dec;60(12):937-8. French. No abstract available.

PMID:
8012323

Supplemental Content

Loading ...
Support Center